Case 1:22-cv-02229-MKV Document 41 Filed 09/02/22 Page 1 of 2
`
`quinn emanuel trial lawyers | new york
`51 Madison Avenue, 22nd Floor, New York, New York 10010-1601 | TEL (212) 849-7000 FAX (212) 849-7100
`
`WRITER'S DIRECT DIAL NO.
`(212) 849-7412
`
`WRITER'S EMAIL ADDRESS
`raynimrod@quinnemanuel.com
`
`9/2/2022
`
`September 2, 2022
`
`VIA ECF
`
`Hon. Mary Kay Vyskocil
`United States District Court
`Southern District of New York
`500 Pearl Street, Room 2230
`New York, NY 10007
`
`Re:
`
`Acuitas Therapeutics Inc. v. Genevant Sciences GmbH and Arbutus Biopharma Corp.,
`Case No. 1:22-cv-02229-MKV
`
`Your Honor:
`
`I represent Defendant Genevant Sciences GmbH and am submitting this letter motion on behalf of
`all the parties in the above-captioned matter to jointly request a modest adjustment to the August
`16, 2022, scheduling order (ECF No. 37), which governs the filing deadlines applicable to
`Plaintiff’s forthcoming amended complaint and Defendants’ motion to dismiss.
`
`Under the existing order, Plaintiff’s amended complaint is due on or before September 6, 2022,
`Defendants’ motion to dismiss the amended complaint is due within 14 days thereafter, and
`opposition and reply briefs are due on the schedule set forth in Local Rule 6.1(b). The parties have
`conferred regarding those dates, including in light of counsel’s preexisting professional
`commitments, and hereby jointly and respectfully request that those filing dates be adjusted as
`follows: Plaintiff’s amended complaint shall be filed on September 6, 2022; Defendants’ motion
`to dismiss shall be filed on October 4, 2022; Plaintiff’s opposition to Defendants’ motion shall be
`filed on November 1, 2022; and Defendants’ reply in support of their motion shall be filed on
`November 16, 2022. There have been no previous requests for adjournments or extensions of
`these deadlines.
`
`Respectfully submitted,
` /s/ Raymond N. Nimrod
`Raymond N. Nimrod
`Counsel for Defendant Genevant Sciences GmbH
`
`quinn emanuel urquhart & sullivan, llp
`ATLANTA | AUSTIN | BOSTON | BRUSSELS | CHICAGO | DOHA | HAMBURG | HONG KONG | HOUSTON | LONDON | LOS ANGELES | MANNHEIM |
`MIAMI | MUNICH | NEUILLY-LA DEFENSE | NEW YORK | PARIS | PERTH | RIYADH | SALT LAKE CITY | SAN FRANCISCO | SEATTLE | SHANGHAI |
`SILICON VALLEY | STUTTGART | SYDNEY | TOKYO | WASHINGTON, DC | ZURICH
`
`USDC SDNY
`DOCUMENT
`ELECTRONICALLY FILED
`DOC #:
`
`
`
`DATE FILED:
`
`
`
`

`

`Case 1:22-cv-02229-MKV Document 41 Filed 09/02/22 Page 2 of 2
`
`cc:
`
`Daralyn J. Durie
`Eric C. Wiener
`DURIE TANGRI LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`(415) 362-6666
`
`Kira A. Davis
`DURIE TANGRI LLP
`953 E. 3rd Street
`Los Angeles, CA 90013
`(213) 992-4499
`
`Attorneys for Defendant Arbutus
`Biopharma Corp.
`
`Nicholas Groombridge
`Eric Alan Stone
`Josephine Young
`Allison C. Penfield
`PAUL, WEISS, RIFKIND, WHARTON &
`GARRISON LLP
`1285 Avenue of the Americas
`New York, NY 10019
`(212) 373-2000
`
`Saurabh Gupta
`PAUL, WEISS, RIFKIND, WHARTON &
`GARRISON LLP
`2001 K Street, NW
`Washington, DC 20006
`(202) 223-7300
`
`Attorneys for Plaintiff Acuitas
`Therapeutics Inc.
`
`9/2/2022
`
`2
`
`